Cencora Inc

Cencora Inc(COR)股票分析

$340.000

-0.918 (-0.27%)收盘时

Loading chart…
最高
342.180
开盘
338.130
成交量加权均价
339.55
成交量
1.03M
市值
44.89B
最低
336.470
成交额
350.20M
企业价值/息税折旧摊销前利润(TTM)
12.29

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

AI 分析 of Cencora Inc (COR)

买入

Cencora Inc is a good buy right now due to its current price of $340.92 being below the analyst price targets, with Baird and Citi both setting targets at $370. The RSI is at 87.341, indicating strong momentum, and the company has shown a solid revenue growth trend with Q2 revenue at $78.4 billion, up 3.8% year-over-year. However, a key risk is the high debt-to-equity ratio of 361.93%, which could impact financial stability.

分析师评级(15)

上行空间 +22.17%
持有
7 买入
8 持有
0 卖出
当前: 340.00
最低
400.00
平均
415.38
最高
440.00

RBC Capital

2026-08-19

目标价

$330

Sector Perform

Leerink

2026-08-12

目标价

—

跑赢大盘

Morgan Stanley

2026-08-07

目标价

$346

增持

Baird

2026-08-06

目标价

$370

跑赢大盘

Evercore ISI

2026-08-06

目标价

$350

跑赢大盘

估值指标

Cencora Inc(COR)当前预期市盈率为 15.70,5 年平均预期市盈率为 15.40。

预期市盈率

合理
5 年均值 P/E
15.40
当前P/E
15.70
高估
17.62
低估
13.18

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
11.49
当前EV/EBITDA
12.29
高估
13.67
低估
9.31

预期市销率

高估
5 年均值 P/S
0.15
当前P/S
0.19
高估
0.17
低估
0.12

Alphio AI 对 COR 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%COR

$387.16

情景价格

基

基准

基准 · 50%COR

$367.49

情景价格

悲

悲观

悲观 · 25%COR

$348.87

情景价格

持有 COR 的大户

W

Walgreens Boots Alliance Holdings LLC

+ 持有COR

+13.11%

3个月收益率

C

Carmignac Gestion SA

+ 持有COR

+7.33%

3个月收益率

D

Diversified Trust Company, Inc.

+ 持有COR

+7.17%

3个月收益率

T

Trajan Wealth, L.L.C.

+ 持有COR

+6.90%

3个月收益率

S

Squarepoint OPS LLC

+ 持有COR

+6.44%

3个月收益率

A

ATB Investment Management Inc.

+ 持有COR

+4.98%

3个月收益率

事件时间线

2026-09-25 (ET)

08:30:00

Cencora Appoints Robert Sanchez as Independent Director

2026-08-12 (ET)

13:00:00

Cencora Reaffirms FY2026 EPS Guidance of $17.75 to $17.95

13:00:00

Cencora Sees FY26 Adjusted EPS of $17.75-$17.95

2026-06-15 (ET)

16:30:00

Cencora HR Executive Announces Retirement

资讯

COR 常见问题 —— 由 Alphio AI 解答

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

Cencora Inc is a good buy right now due to its current price of $340.92 being below the analyst price targets, with Baird and Citi both setting targets at $370. The RSI is at 87.341, indicating strong momentum, and the company has shown a solid revenue growth trend with Q2 revenue at $78.4 billion, up 3.8% year-over-year. However, a key risk is the high debt-to-equity ratio of 361.93%, which could impact financial stability.

15 analysts cover COR: 7 rate it Buy, 8 Hold and 0 Sell. The average price target is 415.38.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易